CITRYLL

citryll-logo

Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll was established in 2015 and is headquartered in Oss, The Netherlands.

#SimilarOrganizations #People #Financial #Website #More

CITRYLL

Social Links:

Industry:
Biopharma Biotechnology Medical Medical Device Neuroscience

Founded:
2015-01-01

Address:
Oss, Noord-Brabant, The Netherlands

Country:
The Netherlands

Website Url:
http://www.citryll.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
20.79 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Euro WordPress 6.0 WPForms


Similar Organizations

cerevance-logo

Cerevance

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.

rainier-therapeutics-logo

Rainier Therapeutics

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.

tiburio-therapeutics-logo

Tiburio Therapeutics

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.

Current Employees Featured

helmuth-van-es_image

Helmuth van Es
Helmuth van Es CEO @ Citryll
CEO
2015-04-01

renato-chirivi_image

Renato Chirivi
Renato Chirivi CSO @ Citryll
CSO

Founder


helmuth-van-es_image

Helmuth van Es

renato-chirivi_image

Renato Chirivi

Investors List

seventure-partners_image

Seventure Partners

Seventure Partners investment in Series B - Citryll

brightgene_image

BrightGene

BrightGene investment in Series B - Citryll

brabantse-ontwikkelings-maatschappij-bom_image

BOM

BOM investment in Series B - Citryll

biogeneration-ventures_image

BioGeneration Ventures

BioGeneration Ventures investment in Series B - Citryll

modiquest-b-v_image

ModiQuest B.V.

ModiQuest B.V. investment in Series B - Citryll

curie-capital_image

Curie Capital

Curie Capital investment in Series A - Citryll

brightgene_image

BrightGene

BrightGene investment in Series A - Citryll

modiquest-b-v_image

ModiQuest B.V.

ModiQuest B.V. investment in Series A - Citryll

bom-brabant-ventures_image

BOM Brabant Ventures

BOM Brabant Ventures investment in Series A - Citryll

Official Site Inspections

http://www.citryll.com Semrush global rank: 4.9 M Semrush visits lastest month: 1.78 K

  • Host name: 185-151-30-223.ptr4.stackcp.net
  • IP address: 185.151.30.223
  • Location: United Kingdom
  • Latitude: 51.4964
  • Longitude: -0.1224
  • Timezone: Europe/London

Loading ...

More informations about "Citryll"

Citryll - Crunchbase Company Profile & Funding

Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers โ€ฆSee details»

About Citryll - Citryll

About Citryll Targeting NETs, transforming inflammatory disease outcomes Citryll is pioneering an innovative approach to immune mediated inflammatory diseases. Targeting NETs as a โ€ฆSee details»

Citryll - Funding, Financials, Valuation & Investors - Crunchbase

Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. ...See details»

Citryll BV - Drug pipelines, Patents, Clinical trials - Synapse

Explore Citryll BV with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 12 news, and 1 literature, Disease Domain:Immune System Diseases, Technology โ€ฆSee details»

Citryll | Forbion

Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases. Industry Biotech citryll.com Building RK โ€ฆSee details»

Dutch biotech startup Citryll raises โ‚ฌ85m Series B to advance its โ€ฆ

Dec 10, 2024 The funding round was co-led by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation โ€“ JJDC, Inc.), Forbion and โ€ฆSee details»

Dutch biotech firm Citryll raises โ‚ฌ85m โ€“ Euro Financial Review

Dec 9, 2024 โ€œThe funding round was co-led by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation โ€“ JJDC, Inc.), Forbion and โ€ฆSee details»

Citryll announces appointments of Eduardo Bravo as CEO and Tim โ€ฆ

With the addition of these industry experts with strong track records, we have composed a leadership team that is well-positioned to successfully reach the next stage of clinical and โ€ฆSee details»

Citryll - Products, Competitors, Financials, Employees, โ€ฆ

Citryll is a biotech company focused on developing therapeutics for immune-mediated inflammatory diseases. Use the CB Insights Platform to explore Citryll's full profile. Citryll - โ€ฆSee details»

Citryll | BioGeneration Ventures

Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases. Year 2020 Field Immunology Status โ€ฆSee details»

Citryll raises 85 million euros | The Pharmaletter

Dec 9, 2024 The funding round was co-led by Johnson & Johnson (NYSE: JNJ), through its corporate venture capital organization, Johnson & Johnson Innovation โ€“ JJDC, Forbion and โ€ฆSee details»

Dutch Biotech Citryll Secures โ‚ฌ85M Funding from J&J and Novartis โ€ฆ

Dec 10, 2024 Citryll, a Dutch biotech company, has raised โ‚ฌ85 million in a Series B funding round co-led by Johnson & Johnson Innovation โ€“ JJDC, Inc., Forbion, and Novartis Venture โ€ฆSee details»

Citryll Raises EUR 85 Million Series B to Advance Novel NET

Dec 9, 2024 Citryll is developing the first NET-targeting therapy, and potentially creating a new class of therapeutics with broad applications across immune-mediated inflammatory diseases. โ€ฆSee details»

Lonza, Citryll Enter Manufacturing Partnership โ€“ Contract Pharma

Sep 10, 2019 The Netherlands-based biotech Citryll and contract development and manufacturing organization (CDMO) Lonza have entered a partnership to develop and โ€ฆSee details»

CIT-013 - Drug Targets, Indications, Patents - Synapse - Patsnap

The funding round was co-led by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation โ€“ JJDC, Inc.), Forbion and Novartis Venture โ€ฆSee details»

Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 โ€ฆ

Oss, Netherlands โ€“ 20 February 2025 โ€“ Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil โ€ฆSee details»

Citryll Announces Dosing of the First Healthy Volunteer in a

Aug 17, 2021 OSS, The Netherlands--(BUSINESS WIRE)-- Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the โ€ฆSee details»

Hidradenitis Suppurativa - Citryll

Hidradenitis Suppurativa Hidradenitis Suppurativa severely affects the lives of millions of patients Citryll is currently planning a Phase 2a trial of CIT-013 in Hidradenitis Suppurativa (HS).HS is โ€ฆSee details»

Citryll annonce lโ€™achèvement du recrutement des patients et du โ€ฆ

Jul 31, 2024 Citryll, une société de biotechnologie au stade clinique qui développe des traitements de premier ordre pour traiter les maladies inflammatoires à médiation immunitaire, โ€ฆSee details»

linkstock.net © 2022. All rights reserved